STAT+: The state of biotech M&A 2024

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Biotech M&A has been disappointing. Perhaps the trend will improve before we reach the holidays, but I can only opine on what’s transpired, and honestly, that’s not much. 

By my count, there have been 35 transactions totaling $45 billion. My M&A list might differ from others, but I tried to capture all the meaningful activity, year to date.

Continue to STAT+ to read the full story…